Maxim Positive on Inovio Pharma's (INO) Zika Virus Vaccine Collaboration; Reaffirms at 'Buy'
Tweet Send to a Friend
Maxim affirms Inovio Pharmaceuticals (Nasdaq INO) with a Buy rating and $14 price target after the company announced a new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
